JP2022524559A5 - - Google Patents

Info

Publication number
JP2022524559A5
JP2022524559A5 JP2021578166A JP2021578166A JP2022524559A5 JP 2022524559 A5 JP2022524559 A5 JP 2022524559A5 JP 2021578166 A JP2021578166 A JP 2021578166A JP 2021578166 A JP2021578166 A JP 2021578166A JP 2022524559 A5 JP2022524559 A5 JP 2022524559A5
Authority
JP
Japan
Prior art keywords
optionally substituted
group
alkyl
adenosine
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021578166A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524559A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/022028 external-priority patent/WO2020185859A1/en
Publication of JP2022524559A publication Critical patent/JP2022524559A/ja
Publication of JP2022524559A5 publication Critical patent/JP2022524559A5/ja
Priority to JP2024111629A priority Critical patent/JP2024138445A/ja
Pending legal-status Critical Current

Links

JP2021578166A 2019-03-12 2020-03-11 がん遺伝子によって促進されるがんの処置 Pending JP2022524559A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024111629A JP2024138445A (ja) 2019-03-12 2024-07-11 がん遺伝子によって促進されるがんの処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962817425P 2019-03-12 2019-03-12
US62/817,425 2019-03-12
PCT/US2020/022028 WO2020185859A1 (en) 2019-03-12 2020-03-11 Treatment of oncogene-driven cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024111629A Division JP2024138445A (ja) 2019-03-12 2024-07-11 がん遺伝子によって促進されるがんの処置

Publications (2)

Publication Number Publication Date
JP2022524559A JP2022524559A (ja) 2022-05-06
JP2022524559A5 true JP2022524559A5 (cg-RX-API-DMAC10.html) 2023-03-09

Family

ID=72427708

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021578166A Pending JP2022524559A (ja) 2019-03-12 2020-03-11 がん遺伝子によって促進されるがんの処置
JP2024111629A Pending JP2024138445A (ja) 2019-03-12 2024-07-11 がん遺伝子によって促進されるがんの処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024111629A Pending JP2024138445A (ja) 2019-03-12 2024-07-11 がん遺伝子によって促進されるがんの処置

Country Status (10)

Country Link
US (2) US12453738B2 (cg-RX-API-DMAC10.html)
EP (2) EP3937964B1 (cg-RX-API-DMAC10.html)
JP (2) JP2022524559A (cg-RX-API-DMAC10.html)
KR (1) KR20210137162A (cg-RX-API-DMAC10.html)
CN (1) CN113795267A (cg-RX-API-DMAC10.html)
AU (2) AU2020239048B2 (cg-RX-API-DMAC10.html)
CA (1) CA3133078A1 (cg-RX-API-DMAC10.html)
ES (1) ES3070946T3 (cg-RX-API-DMAC10.html)
PL (1) PL3937964T3 (cg-RX-API-DMAC10.html)
WO (1) WO2020185859A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3823614A4 (en) 2018-07-18 2022-03-30 Arcus Biosciences, Inc. SOLID FORMS OF AN AZOLOPYRIMIDINE COMPOUND
CA3135487A1 (en) 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
TWI821559B (zh) * 2019-04-28 2023-11-11 大陸商上海和譽生物醫藥科技有限公司 一種cd73抑制劑,其製備方法和應用
CA3179320A1 (en) 2020-06-17 2021-12-23 Arcus Biosciences, Inc. Crystalline forms of a cd73 inhibitor and uses thereof
WO2022091048A1 (en) 2020-10-30 2022-05-05 Integral Biosciences Private Limited Ectonucleotide pyrophosphatase-phosphodiesterase-1 (enpp1) inhibitors and uses thereof
CA3231951A1 (en) * 2021-09-15 2023-03-23 Shuangni ZHAO Polymorph and application of pyrimidine derivative and pharmaceutically acceptable salt thereof
CN114574580B (zh) * 2022-02-14 2022-11-29 山东大学 靶向a2br联合化疗在三阴性乳腺癌治疗中的应用
CN120091809A (zh) 2022-10-20 2025-06-03 艾库斯生物科学有限公司 Cd73化合物的冻干制剂
WO2024225750A1 (ko) * 2023-04-25 2024-10-31 아이디언스 주식회사 Atm 및 asxl1 공동 돌연변이 암의 치료를 위한 차세대 parp 억제제의 항암제 용도
CN117414426A (zh) * 2023-09-18 2024-01-19 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) K-ras基因在用于制备调节体内腺苷含量试剂的用途和抗肿瘤应用

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092020A2 (en) 2001-03-23 2002-11-21 The Burnham Institute Compositions and methods for modulating bone mineral deposition
US20030078232A1 (en) 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
JP2005516917A (ja) 2001-12-12 2005-06-09 アメリカ合衆国 細胞外アデノシン阻害剤およびアデノシン受容体阻害剤を用いて免疫応答および炎症を増強するための方法
WO2004079013A1 (en) 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US20090142347A1 (en) 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール,インク. Gitr結合分子およびその使用
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
JP2009519236A (ja) 2005-11-30 2009-05-14 キャン−ファイト・バイオファーマ・リミテッド A3アデノシンレセプター抗体の治療的使用
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
EP3153526B1 (en) 2008-01-31 2020-09-23 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
IN2015DN02826A (cg-RX-API-DMAC10.html) 2009-09-03 2015-09-11 Merck Sharp & Dohme
DK2510010T3 (en) 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
EP3943154A1 (en) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
WO2012031008A2 (en) * 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
WO2012031320A1 (en) 2010-09-06 2012-03-15 Peter Maccallum Cancer Institute Cancer diagnostic
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
WO2012085132A1 (en) 2010-12-22 2012-06-28 Orega Biotech Antibodies against human cd39 and use thereof
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
AU2013222345B2 (en) 2012-02-22 2017-09-07 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as TNAP inhibitors
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
US9307487B2 (en) 2013-08-30 2016-04-05 Qualcomm Incorporated Methods and systems for improved utilization of a wireless medium
EP3134411B1 (en) 2014-04-25 2021-06-30 Boehringer Ingelheim International GmbH Purine derivatives as cd73 inhibitors for the treatment of cancer
RS62003B2 (sr) * 2014-11-10 2025-01-31 Medimmune Ltd Vezujući molekuli specifični za cd73 i njihove upotrebe
EP3789403A1 (en) 2014-11-11 2021-03-10 MedImmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
WO2017040930A2 (en) 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
EP3380519A1 (en) 2015-11-23 2018-10-03 Innate Pharma Cd39 vascular isoform targeting agents
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
LT3399984T (lt) 2016-01-08 2023-11-10 Arcus Biosciences, Inc. 5'-nukleotidazės, ekto moduliatoriai ir jų panaudojimas
AU2017228470A1 (en) 2016-03-04 2018-08-30 Bristol-Myers Squibb Company Combination therapy with anti-CD73 antibodies
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
WO2018067424A1 (en) 2016-10-03 2018-04-12 Arcus Biosciences, Inc. Inhibitors of adenosine 5'-nucleotidase
CN110022881B (zh) 2016-11-18 2023-05-02 艾库斯生物科学有限公司 Cd73介导的免疫抑制的抑制剂
KR102638592B1 (ko) 2016-12-22 2024-02-19 안텐진 테라퓨틱스 리미티드 엑토뉴클레오티다제 억제제 및 이의 용도
ES2985986T3 (es) 2017-01-06 2024-11-08 Bicyclerd Ltd Conjugado biciclo para tratar el cáncer
MX389798B (es) 2017-01-20 2025-03-20 Arcus Biosciences Inc Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer.
CA3045376C (en) 2017-01-24 2022-08-30 I-Mab Anti-cd73 antibodies and uses thereof
WO2018183635A1 (en) 2017-03-31 2018-10-04 Peloton Therapeutics, Inc. Cd73 inhibitors and uses thereof
WO2018187512A1 (en) 2017-04-04 2018-10-11 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
WO2018187484A1 (en) * 2017-04-04 2018-10-11 Corvus Pharmaceuticals, Inc. Methods of treating cancer
US20190022096A1 (en) 2017-04-04 2019-01-24 Corvus Pharmaceuticals, Inc. Methods of treating cancer
EP3618829B1 (en) 2017-05-05 2023-06-07 Arcus Biosciences, Inc. Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
WO2018208727A1 (en) 2017-05-08 2018-11-15 Eternity Bioscience Inc. Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
CN110636846B (zh) 2017-05-17 2023-05-16 艾库斯生物科学有限公司 用于治疗癌症相关疾病的喹唑啉吡唑衍生物
KR102770106B1 (ko) 2017-06-08 2025-02-21 블랙 벨트 테라퓨틱스 리미티드 Cd38 조정 항체
MX2019015885A (es) 2017-06-22 2020-09-10 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
US20200172628A1 (en) * 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
CN107286146B (zh) 2017-07-05 2020-07-31 上海肇钰医药科技有限公司 作为腺苷a2a受体拮抗剂的4-氨基嘧啶衍生物及其用途
WO2019023635A1 (en) 2017-07-27 2019-01-31 Stingray Therapeutics, Inc. SUBSTITUTED 3 H-IMIDAZO (4,5-C) PYRIDINE AND 1H-PYRROLO (2,3-C) PYRIDINE SERIES OF A NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR A GENE MODULATOR INTERFERON (STING) AS IMMUNOTHERAPEUTIC AGENTS AGAINST CANCER
JP7299873B2 (ja) 2017-08-16 2023-06-28 ブラック ベルト セラピューティクス リミテッド Cd38抗体
AU2018316521B2 (en) 2017-08-16 2025-01-30 Black Belt Therapeutics Limited CD38 modulating antibody
CA3080976A1 (en) * 2017-11-06 2019-05-09 Corvus Pharmaceuticals, Inc. Adenosine pathway inhibitors for cancer treatment
CA3090922A1 (en) 2018-02-16 2019-08-22 Arcus Biosciences, Inc. Dosing with an azolopyrimidine compound
TWI702954B (zh) 2018-03-01 2020-09-01 美商美國禮來大藥廠 Cd73抑制劑
WO2019173682A1 (en) 2018-03-09 2019-09-12 Arcus Biosciences, Inc. Parenterally administered immune enhancing drugs
CA3096674A1 (en) 2018-04-12 2019-10-17 Bristol-Myers Squibb Company Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
TW202012637A (zh) 2018-04-24 2020-04-01 瑞典商阿斯特捷利康公司 治療癌症之方法
EP3823614A4 (en) 2018-07-18 2022-03-30 Arcus Biosciences, Inc. SOLID FORMS OF AN AZOLOPYRIMIDINE COMPOUND
AU2019312296B2 (en) 2018-07-27 2025-05-29 Arcus Biosciences, Inc. Pyridone A2R antagonists
ES3053198T3 (en) 2018-08-27 2026-01-20 Arcus Biosciences Inc Cd73 inhibitors
EP3863664A1 (en) 2018-10-11 2021-08-18 Pfizer Inc. Dosage regimen for tfpi antagonists
EP3893891A4 (en) 2018-12-13 2022-08-03 Arcus Biosciences, Inc. SOLID FORMS OF A CD73 INHIBITOR AND THEIR USE
CA3135487A1 (en) 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
EP4084870A1 (en) 2020-01-03 2022-11-09 Incyte Corporation Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
US11633416B1 (en) 2020-03-06 2023-04-25 Arcus Biosciences, Inc. Oral formulations of CD73 compounds
CA3179320A1 (en) * 2020-06-17 2021-12-23 Arcus Biosciences, Inc. Crystalline forms of a cd73 inhibitor and uses thereof

Similar Documents

Publication Publication Date Title
JP7190549B2 (ja) Hdac阻害剤とpd-1阻害剤との組み合わせ療法
Azijli et al. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies
JP2022527476A5 (cg-RX-API-DMAC10.html)
JP5931982B2 (ja) (a)ホスホイノシタイド3−キナーゼ阻害剤および(b)Ras/Raf/Mek経路のモジュレーターの配合物
JP2020111618A5 (cg-RX-API-DMAC10.html)
JP2020518627A5 (cg-RX-API-DMAC10.html)
ES2275931T3 (es) Compuestos de aril-urea en combinacion con otros agentes citostaticos o citotoxicos para tratamiento de canceres humanos.
JP7367910B2 (ja) がんの処置
JP2022535120A5 (cg-RX-API-DMAC10.html)
ES2953005T3 (es) Tratamiento para el cáncer
JP2017538677A5 (cg-RX-API-DMAC10.html)
JP2017511360A5 (cg-RX-API-DMAC10.html)
JP2018100302A (ja) 抗腫瘍アルカロイドを用いる、組み合わせの治療法
JP2019518741A5 (cg-RX-API-DMAC10.html)
RU2015118647A (ru) Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr
ES2736030T3 (es) Politerapia para el tratamiento del cáncer de ovario
JP2016512831A5 (cg-RX-API-DMAC10.html)
JP2024147816A (ja) がん治療における免疫モジュレーションのための組合せ
JP2018138570A (ja) 癌の治療のためのamg900の使用
TW201313228A (zh) N-羥基-4-{2-[3-(n,n-二甲基胺基甲基)苯並呋喃-2-基羰基胺基]乙氧基}苯甲醯胺之新穎投藥法
RU2007141398A (ru) НОВЫЕ ПРОИЗВОДНЫЕ ИЗОИНДОЛОВ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ИХ, ИХ ПОЛУЧЕНИЕ И ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ, В ЧАСТНОСТИ, В КАЧЕСТВЕ ИНГИБИТОРОВ АКТИВНОСТИ БЕЛКА-ШАПЕРОНА Hsp90
Li et al. DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo
JP2020521786A5 (cg-RX-API-DMAC10.html)
Kunos et al. Phase I trial of triapine–cisplatin–paclitaxel chemotherapy for advanced stage or metastatic solid tumor cancers
JP2013513614A (ja) 膵臓癌を処置する方法